Skin GVHD Skin GVHD
Conditions
Interventions
Narrow band ultraviolet B(NBUVB) therapy, blood examination
Sponsors
KURODA JUNYA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient who receives treatment between the date of jRCT release and March 31st 2026 2. Post-allogeneic hematopoietic stem cell transplantation patient with treatment-refractory acute skin GVHD which is defined by the disease status which is not improved by 5 days treatment with corticosteroid. 3. Patient with acute skin GVHD which is histologically diagnosed. 4. Grade I to II acute GVHD 5. Patient who is able to have written informed consent for the study enrollment 6. Age between 16 to 70 at the informed consent 7. No restriction for gender 8. Both outpatient and inpatient are eligible 9. Performance status 0-2 defined by Eastern Cooperative Oncology Group criteria
Exclusion criteria
Exclusion criteria: 1. Pregnant female patient 2. Poor control diabetes mellitus 3. Any severe infection 4. Treatment-difficult skin disease other than GVHD 5. Patients with Grade 3 or worse GVHD 6. Patients with photodermatosis, or those take drugs which may cause photodermatosis 7. Patients whom an attending physician consider not appropriate for study enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Rates for complete response, partial response, stable disease, and progressive disease, Duration of response, Sparing effect on calcineurin inhibitor and corticosteroid, Adverse event(s), Profile of white blood cells, blood biochemical data | — |
Contacts
Public ContactJUNYA KURODA
University Hospital Kyoto Prefectural University of Medicine
Outcome results
None listed